Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.
Mol. Ther., Dec;16(12):2022-9 (2008)
Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine.
Cancer Immunol. Immunother., Sep;58(9):1397-405 (2009)
Biologics through chemistry: total synthesis of a proposed dual-acting vaccine targeting ovarian cancer by orchestration of oligosaccharide and polypeptide domains.
J. Am. Chem. Soc., Mar;131(11):4151-8 (2009)
From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine.
J. Am. Chem. Soc., Jul;131(26):9298-303 (2009)
Design and synthesis of potent Quillaja saponin vaccine adjuvants.
J. Am. Chem. Soc., Feb;132(6):1939-45 (2010)
Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins.
Vaccine., Jun;28(26):4260-7 (2010)
Impact of minimal tumor burden on antibody response to vaccination.
Cancer Immunol. Immunother., May;60(5):621-7 (2011)
Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer.
Expert Rev Vaccines., Apr;10(4):463-70 (2011)
Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci.
Cancer Immunol. Immunother., Jan;61(1):9-18 (2012)
Synthesis and Preclinical Evaluation of QS-21 Variants Leading to Simplified Vaccine Adjuvants and Mechanistic Probes.
J. Am. Chem. Soc., Aug;134(32):13448-57 (2012)
Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity.
J. Immunol., May;174(9):5706-12 (2005)
Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity.
Vaccine., Sep;23(39):4727-33 (2005)
Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy.
Cancer Immunol. Immunother., Oct;54(10):1018-25 (2005)
Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates.
J. Am. Chem. Soc., Mar;128(8):2715-25 (2006)
Cancer vaccines targeting carbohydrate antigens.
Hum Vaccin., 2(3):137-43 (2006)
A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma.
Dig. Dis. Sci., Aug;52(8):1964-72 (2007)
Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.
Clin. Cancer Res., May;13(10):2977-85 (2007)
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
Clin. Cancer Res., Jul;13(14):4170-7 (2007)
Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma.
Mol. Ther., Nov;15(11):2044-50 (2007)
Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine.
Angew. Chem. Int. Ed. Engl., 47(34):6395-8 (2008)
Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
Clin. Cancer Res., Nov;9(14):5214-20 (2003)
Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.
J. Clin. Oncol., Dec;21(23):4292-8 (2003)
A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside.
Vaccine., Jul;22(21-22):2904-9 (2004)
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
J. Clin. Oncol., Feb;22(4):610-6 (2004)
Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.
Clin. Cancer Res., Feb;10(3):916-23 (2004)
Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn.
Cancer Immunol. Immunother., May;54(5):424-30 (2005)
Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin.
Clin. Cancer Res., Sep;10(18 Pt 1):6094-100 (2004)
Synthesis of selected LeY and KH-1 analogues: a medicinal chemistry approach to vaccine optimization.
J. Org. Chem., Apr;70(9):3383-95 (2005)
Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
Vaccine., Jan;20(7-8):1030-8 (2002)
Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1.
Int. J. Cancer., Feb;97(5):660-7 (2002)
Vaccines for melanoma: translating basic immunology into new therapies.
Lancet Oncol., Apr;2(4):205-11 (2001)
Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies.
Int. J. Cancer., May;99(2):207-12 (2002)
Vaccination with CD20 peptides induces a biologically active, specific immune response in mice.
Blood., May;99(10):3748-55 (2002)
T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.
Clin. Cancer Res., May;8(5):967-72 (2002)
Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.
J. Clin. Oncol., Jun;20(11):2610-5 (2002)
Clinical results using biochemotherapy as a standard of care in advanced melanoma.
Melanoma Res., Aug;12(4):381-7 (2002)
On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines.
Proc. Natl. Acad. Sci. U.S.A., Oct;99(21):13699-704 (2002)
Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma.
Melanoma Res., Apr;13(2):189-96 (2003)
A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
Cancer Immunol. Immunother., Oct;52(10):608-16 (2003)
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
J. Clin. Oncol., Sep;21(17):3351-6 (2003)
Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.
Proc. Natl. Acad. Sci. U.S.A., May;96(10):5710-5 (1999)
Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases.
Cancer Res., Jul;58(13):2844-9 (1998)
Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.
Clin. Cancer Res., Oct;5(10):2773-9 (1999)
Immunization of mice with fucosyl-GM1 conjugated with keyhole limpet hemocyanin results in antibodies against human small-cell lung cancer cells.
Cancer Immunol. Immunother., Dec;48(9):483-92 (1999)
Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
Int. J. Cancer., Mar;85(5):659-66 (2000)
Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens.
Proc. Natl. Acad. Sci. U.S.A., Mar;97(6):2719-24 (2000)
Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.
Clin. Cancer Res., Mar;6(3):874-9 (2000)
Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside.
Melanoma Res., Aug;7 Suppl 2:S155-62 (1997)
Augmenting the immunogenicity of carbohydrate tumor antigens.
Semin. Cancer Biol., Dec;6(6):357-66 (1995)
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
Clin. Cancer Res., May;6(5):1693-701 (2000)
Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues.
J. Clin. Immunol., Mar;20(2):85-93 (2000)
Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin.
Clin. Cancer Res., Dec;6(12):4658-62 (2000)
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial.
Proc. Natl. Acad. Sci. U.S.A., Mar;98(6):3270-5 (2001)
Construction of cancer vaccines with carbohydrate and protein (peptide) tumor antigens.
Curr. Opin. Immunol., Oct;4(5):624-9 (1992)
Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma.
Vaccine., Nov;12(14):1275-80 (1994)
Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.
Clin. Cancer Res., Apr;2(4):679-86 (1996)
Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach.
Semin. Oncol., Dec;23(6 Suppl 14):41-8 (1996)
Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides.
Int. J. Cancer., Sep;73(1):42-9 (1997)
Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale.
Cancer Immunol. Immunother., Oct;45(1):1-9 (1997)
Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens.
Int. J. Cancer., Sep;73(1):50-6 (1997)
Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans.
Cancer Immunol. Immunother., Oct;45(1):10-9 (1997)
A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm.
Glycoconj. J., Mar;15(3):217-21 (1998)
Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens.
Clin. Cancer Res., Nov;4(11):2669-76 (1998)
Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies.
Clin. Cancer Res., Jan;5(1):77-81 (1999)
Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells.
Cancer Immunol. Immunother., Apr;48(1):1-8 (1999)
Ectopic dendrites occur only on cortical pyramidal cells containing elevated GM2 ganglioside in alpha-mannosidosis.
Proc. Natl. Acad. Sci. U.S.A., Dec;88(24):11330-4 (1991)
Impact of minimal tumor burden on antibody response to vaccination
Cancer Immunology, Immunotherapy
The Known Immunologically Active Components of Astragalus Account for Only a Small Proportion of the Immunological Adjuvant Activity When Combined with Conjugate Vaccines
A high-throughput O-glycopeptide discovery platform for seromic profiling
Journal of Proteome Research
Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins
Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes